Autolus Therapeutics plc

5.16-0.3300-6.01%Vol 810.69K1Y Perf -63.03%
Jul 27th, 2021 13:15 DELAYED
BID5.16 ASK5.19
Open5.51 Previous Close5.49
Pre-Market- After-Market-
 - -%  - -
Target Price
14.00 
Analyst Rating
Strong Buy 1.20
Potential %
167.18 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.39
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     52.19
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap363.86M 
Earnings Rating
Buy
Price Range Ratio 52W %
4.60 
Earnings Date
5th Aug 2021

Today's Price Range

5.135.53

52W Range

4.6016.78

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-10.88%
1 Month
-21.01%
3 Months
-9.11%
6 Months
-32.22%
1 Year
-63.03%
3 Years
-77.32%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AUTL5.16-0.3300-6.01
AAPL146.01-2.9800-2.00
GOOG2 706.75-86.1400-3.08
MSFT283.93-5.1200-1.77
XOM57.55-0.9300-1.59
WFC45.070.06000.13
JNJ172.380.51000.30
FB365.50-6.9600-1.87
GE13.060.14001.08
JPM151.64-0.0100-0.01
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.62-0.5314.52
Q04 2020-0.75-0.82-9.33
Q03 2020-0.66-0.72-9.09
Q02 2020-0.70-0.6211.43
Q01 2020-0.71-0.6015.49
Q04 2019-0.71-0.93-30.99
Q03 2019-0.87-0.6129.89
Q02 2019-0.76-0.6514.47
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.505.66Positive
9/2021 QR-0.503.85Positive
12/2021 FY-2.036.88Positive
12/2022 FY-1.92-6.08Negative
Next Report Date5th Aug 2021
Estimated EPS Next Report-0.50
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume810.69K
Shares Outstanding70.52M
Trades Count2.73K
Dollar Volume7.55M
Avg. Volume1.23M
Avg. Weekly Volume1.34M
Avg. Monthly Volume1.36M
Avg. Quarterly Volume1.82M

Autolus Therapeutics plc (NASDAQ: AUTL) stock closed at 5.49 per share at the end of the most recent trading day (a -0.54% change compared to the prior day closing price) with a volume of 1.86M shares and market capitalization of 363.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 298 people. Autolus Therapeutics plc CEO is Christian Itin.

The one-year performance of Autolus Therapeutics plc stock is -63.03%, while year-to-date (YTD) performance is -38.59%. AUTL stock has a five-year performance of %. Its 52-week range is between 4.6 and 16.78, which gives AUTL stock a 52-week price range ratio of 4.60%

Autolus Therapeutics plc currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 1.45, a price-to-sale (PS) ratio of 286.13, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.04%, a ROC of -45.70% and a ROE of -48.07%. The company’s profit margin is -%, its EBITDA margin is -9 886.00%, and its revenue ttm is $1.35 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Autolus Therapeutics plc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Autolus Therapeutics plc’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Autolus Therapeutics plc is Strong Buy (1.2), with a target price of $14, which is +167.18% compared to the current price. The earnings rating for Autolus Therapeutics plc stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Autolus Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Autolus Therapeutics plc has a Sell technical analysis rating based on Technical Indicators (ADX : 14.40, ATR14 : 0.43, CCI20 : -146.50, Chaikin Money Flow : -0.10, MACD : -0.28, Money Flow Index : 32.17, ROC : -16.44, RSI : 34.11, STOCH (14,3) : 4.22, STOCH RSI : 0.00, UO : 40.51, Williams %R : -95.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Autolus Therapeutics plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
5 (83.33 %)
4 (80.00 %)
Moderate Buy
1 (20.00 %)
1 (16.67 %)
1 (20.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.17
Strong Buy
1.20

Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.

CEO: Christian Itin

Telephone: +44 2038296230

Address: 58 Wood Lane, London W12 7RZ, , GB

Number of employees: 298

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

64%36%

Bearish Bullish

55%45%

News

Stocktwits